...
首页> 外文期刊>European journal of cardio-thoracic surgery: Official journal of the European Association for Cardio-thoracic Surgery >Evaluation of isolated lung perfusion as neoadjuvant therapy of lung metastases using a novel in vivo pig model: II. High-dose cisplatin is well tolerated by the native lung tissue.
【24h】

Evaluation of isolated lung perfusion as neoadjuvant therapy of lung metastases using a novel in vivo pig model: II. High-dose cisplatin is well tolerated by the native lung tissue.

机译:使用新型体内猪模型评估分离的肺灌注作为肺转移的新辅助疗法:II。天然肺组织对高剂量的顺铂有很好的耐受性。

获取原文
获取原文并翻译 | 示例

摘要

Objective: Efficacy of in vivo isolated lung perfusion (ILP) with cisplatin could be shown in different rodent tumor models. Despite the use of this alternative therapeutical strategy in very few patients with lung metastases, there are no systematic studies regarding the tolerance of the native lung tissue in large animal models or humans. Methods: In a novel ILP pig model, groups with two different concentrations of cisplatin (group CP150: 150 mg/m(2) cisplatin, [Formula: see text] group CP300: 300 mg/m(2) cisplatin, [Formula: see text] ) were compared with a control group ( [Formula: see text] ) and a Sham group ( [Formula: see text] ) concerning the influence on hemodynamic, ventilatory and gas exchange parameters as well as on structural integrity of the lung. In the additional CP300-HT group the potentially cumulative effect of hyperthermia and high-dose cisplatin perfusion was evaluated (300 mg/m(2) cisplatin, 41.5 degrees C, [Formula: see text] ). Following the ILP of the left lung for 40 min, right main bronchus and right pulmonary arteries were clamped and survival as well as lung function parameters were dependent on the previously perfused lung for the 6-h-reperfusion period. Quantification of histological acute lung injury was performed using the score of Chiang. ANOVA, ANOVA with repeated measures and Pearson's correlation estimation were applied for statistical evaluation. Results: All animals survived ILP and the entire reperfusion period. Platinum levels of the perfusate and lung tissue showed a significant correlation with the dose given [Formula: see text] but no correlation with the very low plasma levels in all groups [Formula: see text] ILP resulted in a slight deterioration of most functional parameters compared to the Sham group. Although there were no differences between the perfusion groups regarding hemodynamic and ventilatory parameters, gas exchange parameters (pO(2)/FiO(2)-index, pCO(2), AADO(2)) demonstrated a trend toward dose-related functional impairment. Histological evaluation confirmed a dose-depending damage of lung tissue ( [Formula: see text] correlation coefficient 0.670). The hyperthermic ILP with high-dose cisplatin led to improved gas exchange parameters and a reduction of morphological lung damage. Conclusions: In vivo ILP with high-dose cisplatin represents a safe procedure in this pig model. Hyperthermic perfusion up to 41.5 degrees C was beneficial to reduce the acute lung injury. The promising results of this study might be used for initiation of clinical trials as an alternative treatment in patients with a very poor prognosis.
机译:目的:在不同的啮齿动物肿瘤模型中,可以显示体内离体肺灌注(ILP)与顺铂的疗效。尽管在极少数患有肺转移的患者中使用了这种替代性治疗策略,但是在大型动物模型或人类中,尚无关于天然肺组织耐受性的系统研究。方法:在一种新型的ILP猪模型中,使用两种不同浓度的顺铂组(CP150组:150 mg / m(2)顺铂,[公式:参见正文] CP300组:300 mg / m(2)顺铂,[公式:与对照组(scheme)和假手术(sham)组(scheme)进行比较,研究对血液动力学,通气和气体交换参数以及肺结构完整性的影响。在另外的CP300-HT组中,评估了热疗和大剂量顺铂灌注的潜在累积效应(300 mg / m(2)顺铂,41.5摄氏度,[化学式:见正文])。左肺ILP持续40分钟后,右主支气管和右肺动脉被夹住,在6 h再灌注期间,存活率和肺功能参数取决于先前灌注的肺。使用Chiang评分对组织学急性肺损伤进行量化。方差分析,采用重复测量的方差分析和皮尔森相关估计用于统计评估。结果:所有动物均在ILP和整个再灌注期间存活。灌注液和肺组织中的铂水平与所给予的剂量呈显着相关[公式:参见文本],但与所有组中血浆水平非常低无关[公式:参见文本] ILP导致大多数功能参数略有下降与深水组相比。尽管灌注组之间在血流动力学和通气参数方面没有差异,但是气体交换参数(pO(2)/ FiO(2)-指数,pCO(2),AADO(2))显示了剂量相关功能损害的趋势。组织学评估证实了肺组织的剂量依赖性损害([公式:见正文]相关系数0.670)。具有大剂量顺铂的高温ILP导致改善的气体交换参数并减少了肺部形态损伤。结论:体内ILP与大剂量顺铂在该猪模型中代表了一种安全的方法。高达41.5摄氏度的高温灌注有利于减少急性肺损伤。这项研究的有希望的结果可能被用于启动临床试验,作为预后极差的患者的替代疗法。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号